Is the price fair?
What ATRC's price assumes
AtriCure, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 2.53× revenue.
2.53
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 3.7%
Free cash flow yield · Medical Instruments & Supplies median 3.7%
- Growth the price implies
- +9.7%
Growth the price implies · The price pays for +9.7% free cash flow growth a year for a decade; revenue has grown +16% a year over the last three.
- Price / book
- 2.85
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 2.85
- EV / EBIToperating margin −0.54%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 2.38
- Free cash flow, trailing twelve months
- $54M
- Market capitalisation
- $1.46B
- 3-year revenue growth
- +16%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #10 of 27 by Smart Score